MELPHALAN - A POTENTIAL NEW AGENT IN THE TREATMENT OF CHILDHOOD RHABDOMYOSARCOMA

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (1) , 91-96
Abstract
Melphalan was evaluated against a series of 7 childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and 1 from a patient refractory to conventional therapy. At the maximum tolerated dose (LD 10) a single administration of melphalan caused complete regressions of advanced tumor in 6 of 7 lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin and dactinomycin in the model.

This publication has 0 references indexed in Scilit: